Page last updated: 2024-08-22

lutetium and sirolimus

lutetium has been researched along with sirolimus in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Borkowski, S; Braun, F; Dumont, RA; Maecke, H; Mansi, R; Reubi, JC; Tamma, M; Weber, WA	1
Costa, FP; de Herder, WW; Feelders, RA; Gumz, B; Kaltsas, G; Kamp, K; Kwekkeboom, DJ	1

Other Studies

2 other study(ies) available for lutetium and sirolimus

Article	Year
Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:5 Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Female; Gene Expression Regulation, Neoplastic; Humans; Lutetium; Male; Mice; Molecular Targeted Therapy; Oligopeptides; Prostatic Neoplasms; Radioisotopes; Receptors, Bombesin; Sirolimus	2013
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate. Endocrine-related cancer, 2013, Volume: 20, Issue:6 Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate	2013

Article

Year

Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:5

Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Female; Gene Expression Regulation, Neoplastic; Humans; Lutetium; Male; Mice; Molecular Targeted Therapy; Oligopeptides; Prostatic Neoplasms; Radioisotopes; Receptors, Bombesin; Sirolimus

2013

Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.

Endocrine-related cancer, 2013, Volume: 20, Issue:6

Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate

2013